Lipid-encapsulated mRNA encoding an extended serum half-life interleukin-22 ameliorates metabolic disease in mice
S Canali, AW Fischer, M Nguyen, K Anderson, L Wu… - Molecular …, 2024 - Elsevier
Abstract Objective Interleukin (IL)-22 is a potential therapeutic protein for the treatment of
metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated …
metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated …
Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences
Abstract Background Interleukin-22 (IL-22), a cytokine with important functions in anti-
microbial defense and tissue repair, has been recently suggested to have beneficial effects …
microbial defense and tissue repair, has been recently suggested to have beneficial effects …
Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22
BACKGROUND & AIMS: Interleukin-22 (IL-22) is a Th17-related cytokine within the IL-10
family and plays an important role in host defense and inflammatory responses in …
family and plays an important role in host defense and inflammatory responses in …
Secretion of recombinant interleukin-22 by engineered Lactobacillus reuteri reduces fatty liver disease in a mouse model of diet-induced obesity
JH Oh, KL Schueler, DS Stapleton, LM Alexander… - MSphere, 2020 - Am Soc Microbiol
The incidence of metabolic syndrome continues to rise globally. In mice, intravenous
administration of interleukin-22 (IL-22) ameliorates various disease phenotypes associated …
administration of interleukin-22 (IL-22) ameliorates various disease phenotypes associated …
Delivery of Synthetic Interleukin‐22 mRNA to Hepatocytes via Lipid Nanoparticles Alleviates Liver Injury
H Ouyang, S Wei, B Gao, X Qian, Y Chen, J Lu, Y Ding… - Small, 2024 - Wiley Online Library
Hepatocellular injury, a pivotal contributor to liver diseases, particularly hepatitis, lacks
effective pharmacological treatments. Interleukin‐22 (IL‐22), crucial for liver cell survival …
effective pharmacological treatments. Interleukin‐22 (IL‐22), crucial for liver cell survival …
Interleukin-18–deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis
K Yamanishi, S Maeda, S Kuwahara-Otani… - Translational …, 2016 - Elsevier
We investigated potential pathophysiological relationships between interleukin 18 (IL-18)
and dyslipidemia, nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis …
and dyslipidemia, nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis …
IL-25 stimulates M2 macrophage polarization and thereby promotes mitochondrial respiratory capacity and lipolysis in adipose tissues against obesity
J Feng, L Li, Z Ou, Q Li, B Gong, Z Zhao, W Qi… - Cellular & molecular …, 2018 - nature.com
Obesity and associated metabolic diseases are characterized by a chronic low-grade
inflammatory state with the infiltration of many inflammatory cells, especially macrophages …
inflammatory state with the infiltration of many inflammatory cells, especially macrophages …
Liposomal IL-22 ameliorates liver fibrosis through miR-let7a/STAT3 signaling in mice
AA El-Shorbagy, MW Shafaa, RS Elbeltagy… - International …, 2023 - Elsevier
The therapeutic effect of liposomal IL-22 versus non-liposomal IL-22 on liver fibrosis was
investigated. IL-22 (5 µg/ml) was incorporated into negative charged liposomes …
investigated. IL-22 (5 µg/ml) was incorporated into negative charged liposomes …
Anti‐IL‐17 antibody improves hepatic steatosis by suppressing interleukin‐17‐related fatty acid synthesis and metabolism
W Shi, Q Zhu, J Gu, X Liu, L Lu, X Qian… - Journal of …, 2013 - Wiley Online Library
To investigate the relationship between interleukin‐17 and proteins involved in fatty acid
metabolism with respect to alcoholic liver disease, male ICR mice were randomized into five …
metabolism with respect to alcoholic liver disease, male ICR mice were randomized into five …
MicroRNA-26a–interleukin (IL)-6–IL-17 axis regulates the development of non-alcoholic fatty liver disease in a murine model
Q He, F Li, J Li, R Li, G Zhan, G Li… - Clinical & …, 2017 - academic.oup.com
Non-alcoholic fatty liver disease (NAFLD) is a hepatic presentation of obesity and metabolic
syndrome. MicroRNA 26a (Mir-26a) has been reported to play functions in cellular …
syndrome. MicroRNA 26a (Mir-26a) has been reported to play functions in cellular …